IMProving User experience, Long-term sustainability and Services of EU-OPENSCREEN

EU-OPENSCREEN (EU-OS), the distributed European Research Infrastructure for Chemical Biology and early drug discovery, provides world-class services in high-throughput compound screening and medicinal chemistry to users from academia and industry. As one of the largest open-access initiative globally, EU-OPENSCREEN plays an increasingly important role in facilitating early stage drug discovery in Europe. It recently integrated fragment-based drug discovery and chemoproteomics as two new services, but the increasing complexity of modern drug discovery projects requires an even more comprehensive portfolio and integration of emerging technologies. To ensure that EU-OS continues to offer a comprehensive suite of relevant services and support a growing user community to conduct forefront research, IMPULSE will develop, validate and integrate new services in AI/ML, new chemical modalities, and innovative disease-relevant cell models combined with CRISPR-Cas9/RNAi-based genetic screening. IMPULSE will work towards the implementation of common operational and data standards to increase data reproducibility and FAIRness. Bespoke outreach and training activities will raise awareness among key user groups of its new services and advance operational excellence and reproducibility in pre-clinical drug discovery. New models for pre-competitive drug discovery with industry or charities, and growing ERIC member community will reinforce the sustainability and accessibility of EU-OPENSCREEN.